Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study

Hashim U Ahmed, Richard G Hindley, Louise Dickinson, Alex Freeman, Alex P Kirkham, Mahua Sahu, Rebecca Scott, Clare Allen, Jan Van der Meulen, Mark Emberton, Hashim U Ahmed, Richard G Hindley, Louise Dickinson, Alex Freeman, Alex P Kirkham, Mahua Sahu, Rebecca Scott, Clare Allen, Jan Van der Meulen, Mark Emberton

Abstract

Background: Radical whole-gland therapy can lead to significant genitourinary and rectal side-effects for men with localised prostate cancer. We report on whether selective focal ablation of unifocal and multifocal cancer lesions can reduce this treatment burden.

Methods: Men aged 45-80 years were eligible for this prospective development study if they had low-risk to high-risk localised prostate cancer (prostate specific antigen [PSA] ≤15 ng/mL, Gleason score ≤4 + 3, stage ≤T2), with no previous androgen deprivation or treatment for prostate cancer, and who could safely undergo multiparametric MRI and have a general anaesthetic. Patients received focal therapy using high-intensity focused ultrasound, delivered to all known cancer lesions, with a margin of normal tissue, identified on multiparametric MRI, template prostate-mapping biopsies, or both. Primary endpoints were adverse events (serious and otherwise) and urinary symptoms and erectile function assessed using patient questionnaires. Analyses were done on a per-protocol basis. This study is registered with ClinicalTrials.gov, number NCT00561314.

Findings: 42 men were recruited between June 27, 2007, and June 30, 2010; one man died from an unrelated cause (pneumonia) 3 months after treatment and was excluded from analyses. After treatment, one man was admitted to hospital for acute urinary retention, and another had stricture interventions requiring hospital admission. Nine men (22%, 95% CI 11-38) had self-resolving, mild to moderate, intermittent dysuria (median duration 5·0 days [IQR 2·5-18·5]). Urinary debris occurred in 14 men (34%, 95% CI 20-51), with a median duration of 14·5 days (IQR 6·0-16·5). Urinary tract infection was noted in seven men (17%, 95% CI 7-32). Median overall International Index of Erectile Function-15 (IIEF-15) scores were similar at baseline and at 12 months (p=0·060), as were median IIEF-15 scores for intercourse satisfaction (p=0·454), sexual desire (p=0·644), and overall satisfaction (p=0·257). Significant deteriorations between baseline and 12 months were noted for IIEF-15 erectile (p=0·042) and orgasmic function (p=0·003). Of 35 men with good baseline function, 31 (89%, 95% CI 73-97) had erections sufficient for penetration 12 months after focal therapy. Median UCLA Expanded Prostate Cancer Index Composite (EPIC) urinary incontinence scores were similar at baseline as and 12 months (p=0·045). There was an improvement in lower urinary tract symptoms, assessed by International Prostate Symptom Score (IPSS), between baseline and 12 months (p=0·026), but the IPSS-quality of life score showed no difference between baseline and 12 months (p=0·655). All 38 men with no baseline urinary incontinence were leak-free and pad-free by 9 months. All 40 men pad-free at baseline were pad-free by 3 months and maintained pad-free continence at 12 months. No significant difference was reported in median Trial Outcomes Index scores between baseline and 12 months (p=0·113) but significant improvement was shown in median Functional Assessment of Cancer Therapy (FACT)-Prostate (p=0·045) and median FACT-General scores (p=0·041). No histological evidence of cancer was identified in 30 of 39 men biopsied at 6 months (77%, 95% CI 61-89); 36 (92%, 79-98) were free of clinically significant cancer. After retreatment in four men, 39 of 41 (95%, 95% CI 83-99) had no evidence of disease on multiparametric MRI at 12 months.

Interpretation: Focal therapy of individual prostate cancer lesions, whether multifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of early absence of clinically significant prostate cancer.

Funding: Medical Research Council (UK), Pelican Cancer Foundation, and St Peters Trust.

Copyright © 2012 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Schematic diagrams of the types of focal therapy Unilateral one-area ablation (A). Bilateral two-area ablation with preservation of one neurovascular bundle (B). Midline one-area ablation allows preservation of both neurovascular bundles (C). Large red areas represent dominant cancers (index lesions) whereas small green areas represent small low-grade secondary lesions. Grey transparent boxes represent ablation zones on the high-intensity focused ultrasound device.
Figure 2
Figure 2
Sexual function after focal high-intensity focused ultrasound for unifocal and multifocal localised prostate cancer, measured with the International Index of Erectile Function-15 (IIEF-15) questionnaire Two-tailed p values were reported for Wilcoxon signed ranks test comparing baseline and 12-month median scores. Box and whiskers plots indicate median with IQR (boxes), and range (whiskers). Dots are outliers. Median baseline versus 12-month scores: total IIEF-15 (57·5 [IQR 30·0–67·0] vs 47·0 [29·5–63·3], p=0·060; A); IIEF-15 erectile-function domain (24·0 [13·0–29·0] vs 21·0 [10·3–27·3], p=0·042; B); IIEF-15 intercourse-satisfaction domain (9·0 [0·0–12·0] vs 8·0 [0·0–11·0], p=0·454; C); IIEF-15 orgasmic-function domain (10·0 [6·5–10·0] vs 7·0 [5·0–8·5], p=0·003; D); IIEF-15 sexual-desire domain (7·0 [5·0–8·5] vs 7·0 [5·0–8·0], p=0·644; E); IIEF-15 overall-satisfaction domain (7·5 [4·0–9·0] vs 8·0 [6·0–9·0], p=0·257; F).
Figure 3
Figure 3
Continence function after focal high-intensity focused ultrasound for unifocal and multifocal localised prostate cancer, measured with UCLA Expanded Prostate Cancer Index Composite (EPIC) incontinence questionnaire Two-tailed p values were reported for Wilcoxon signed ranks test comparing baseline and 12-month median scores. Median baseline vs 12 month scores: 100 (IQR 86·0–100·0) vs 100 (92·5–100·0, p=0·045). Box and whiskers plots show median with IQR (boxes) and range (whiskers). Dots are outliers.
Figure 4
Figure 4
Urinary function after focal high-intensity focused ultrasound for unifocal and multifocal localised prostate cancer, measured with International Prostate Symptom Score (IPSS) questionnaire Two-tailed p values were reported for Wilcoxon signed ranks test comparing baseline and 12-month median scores. Box and whiskers plots show median with IQR (boxes) and range (whiskers). Dots are outliers. Median baseline versus 12-month International Prostate Symptom Score (IPSS): 8·0 (IQR 5·5–13·0) vs 7·0 (3·0–12·0, p=0·026; A). Median baseline versus 12-month IPSS-quality of life: 1·0 (0·0–2·0) vs 1·0 (1·0–1·0, p=0·655; B).
Figure 5
Figure 5
Quality-of-life outcomes after focal high-intensity focused ultrasound for unifocal and multifocal localised prostate cancer, measured with the Functional Assessment of Cancer Therapy (FACT) questionnaire Two-tailed p values were reported for Wilcoxon signed ranks test comparing baseline and 12-month median scores. Box and whiskers plots show median with IQR (boxes) and range (whiskers). Dots are outliers. Median baseline versus 12-month Trials Outcome Index score: 94·0 (IQR 89·0–97·3) vs 97·5 (91·0–101·0, p=0·113; A). Median baseline versus 12-month Functional Assessment of Cancer Therapy (FACT)-Prostate score: 138·5 (133·0–147·0) vs 145·3 (137·0–152·0, p=0·045; B). FACT-general score: 96·0 (91·0–102·3) vs 102·0 (96·0–105·0, p=0·041; C).
Figure 6
Figure 6
PSA levels after focal high-intensity focused ultrasound for unifocal and multifocal localised prostate cancer Wilcoxon signed ranks test comparing median prostate-specific antigen levels at baseline (6·6 [IQR 5·4–7·7] ng/mL) and at 12 months (1·9 [0·8–3·3] ng/mL; two-tailed p

Figure 7

Trifecta rate after focal high-intensity…

Figure 7

Trifecta rate after focal high-intensity focused ultrasound for unifocal and multifocal localised prostate…

Figure 7
Trifecta rate after focal high-intensity focused ultrasound for unifocal and multifocal localised prostate cancer Patient-reported trifecta outcomes were reported with validated questionnaires. Data are number of patients (%, 95% CI). *Derived using UCLA EPIC urinary domain questions: “over the past 4 weeks how often do you leak urine?” and “over the past 4 weeks how many pads or adult diapers per day did you usually use to control leakage?”. †Before imputation of data, 36 of 36 men were leak-free and pad-free. ‡Before imputation of data, 38 of 38 men were pad-free. §Proportion of men scoring ≥2 on question 2 of IIEF-15: “over the past 4 weeks when you had erections with sexual stimulation, how often were your erections hard enough for penetration?”. ¶Before imputation of data, 29 (88%) of 33 men had erections sufficient for penetration. ‖Phosphodiesterase-5 inhibitors (tadalafil, sildenafil, or vardenafil; percentage calculated with denominator as those achieving erections sufficient for intercourse).
All figures (7)
Figure 7
Figure 7
Trifecta rate after focal high-intensity focused ultrasound for unifocal and multifocal localised prostate cancer Patient-reported trifecta outcomes were reported with validated questionnaires. Data are number of patients (%, 95% CI). *Derived using UCLA EPIC urinary domain questions: “over the past 4 weeks how often do you leak urine?” and “over the past 4 weeks how many pads or adult diapers per day did you usually use to control leakage?”. †Before imputation of data, 36 of 36 men were leak-free and pad-free. ‡Before imputation of data, 38 of 38 men were pad-free. §Proportion of men scoring ≥2 on question 2 of IIEF-15: “over the past 4 weeks when you had erections with sexual stimulation, how often were your erections hard enough for penetration?”. ¶Before imputation of data, 29 (88%) of 33 men had erections sufficient for penetration. ‖Phosphodiesterase-5 inhibitors (tadalafil, sildenafil, or vardenafil; percentage calculated with denominator as those achieving erections sufficient for intercourse).

References

    1. Djulbegovic M, Beyth RJ, Neuberger MM. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543.
    1. Sanda MG, Dunn RL, Michalski J. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261.
    1. Wilt TJ, MacDonald R, Rutks I. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435–448.
    1. Barry MJ, Gallagher PM, Skinner JS, Fowler FJ., Jr Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol. 2012;30:513–518.
    1. Nilsson S, Norlén BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 2004;43:316–381.
    1. Ahmed HU, Akin O, Coleman JA. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int. 2011 published online Nov 11.
    1. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol. 2007;4:632–642.
    1. Ahmed HU, Freeman A, Kirkham A. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185:1246–1254.
    1. McCulloch P, Altman DG, Campbell WB. No surgical innovation without evaluation: the IDEAL recommendations. Lancet. 2009;374:1105–1112.
    1. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate—a 4-year experience. Urology. 2007;70(suppl 6):27–35.
    1. Litwin MS, Hays RD, Fink A. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–1012.
    1. Esper P, Mo F, Chodak G. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument. Urology. 1997;50:920–928.
    1. Rosen RC, Cappelleri JC, Smith MD. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–326.
    1. Rosen RC, Riley A, Wagner G. The international index of erectile function (IIEF) a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830.
    1. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
    1. Punwani S, Emberton M, Walkden M. Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease. Br J Radiol. 2012 published online Jan 17.
    1. Rouvière O, Girouin N, Glas L. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol. 2010;20:48–55.
    1. Machin D, Campbell M, Fayers P. Sample size tables for clinical studies. 2nd edn. Blackwell Science; London: 1997. pp. 21–22.
    1. Ahmed HU, Zacharakis E, Dudderidge T. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer. 2009;101:19–26.
    1. Mohler J, Bahnson RR, Boston B. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162–200.
    1. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–374.
    1. Epstein JI. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J Urol. 2011;186:790–797.
    1. Finley DS, Pouliot F, Shuch B. Ultrasound-based combination therapy: potential in urologic cancer. Expert Rev Anticancer Ther. 2011;11:107–113.
    1. Medical Research Council Health Services and Public Health Research Board . A framework for development and evaluation of RCTs for complex interventions to improve health. Medical Research Council; London: 2000.
    1. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med. 2009;361:1704–1706.
    1. Ahmed HU, Hu Y, Carter T. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol. 2011;186:458–464.
    1. Onik G, Vaughan D, Lotenfoe R. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008;26:500–505.
    1. Lambert EH, Bolte K, Masson P. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69:1117–1120.
    1. Muto S, Yoshii T, Saito K. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol. 2008;38:192–199.
    1. Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2011 published online Oct 28.
    1. El Fegoun AB, Barret E, Prapotnich D. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol. 2011;37:213–219.
    1. Lambert EH, Bolte K, Masson P. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69:1117–1120.
    1. Lindner U, Weersink RA, Haider MA. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol. 2009;182:1371–1377.
    1. Hu Y, Ahmed HU, Taylor Z. MR to ultrasound registration for image-guided prostate interventions. Med Image Anal. 2012;16:687–703.
    1. Langley S, Ahmed HU, Al-Qaisieh B. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int. 2012;109(suppl 1):7–16.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi